- Home
- VIST vs IBRX Comparison
VIST vs IBRX Comparison
Compare VIST & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VIST | IBRX |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | Mexico | United States |
| Employees | 515 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 7.5B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | VIST | IBRX |
|---|---|---|
| Price | $73.86 | $6.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $74.33 | $12.57 |
| AVG Volume (30 Days) | 1.5M | ★ 14.1M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $113,288,000.00 |
| Revenue This Year | $20.93 | $88.59 |
| Revenue Next Year | $20.35 | $131.15 |
| P/E Ratio | $7.99 | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $33.37 | $1.83 |
| 52 Week High | $79.20 | $12.43 |
Technical Indicators
Market Signals| Indicator | VIST | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 63.72 | 43.00 |
| Support Level | $61.96 | $6.54 |
| Resistance Level | $79.20 | $8.42 |
| Average True Range (ATR) | 2.57 | 0.55 |
| MACD | 0.43 | -0.03 |
| Stochastic Oscillator | 93.53 | 3.63 |
Price Performance
Historical ComparisonAbout VIST Vista Energy S.A.B. de C.V. each representing one series A share with no par value
Vista Energy SAB de CV is an independent oil and gas company. It is focused on shale oil and shale gas exploration at its main assets in Vaca Muerta. The company has operations in Argentina and Mexico. The company operates in a single segment- the exploration and production of Crude oil, Natural gas, and LPG. Geographically, It operates in Argentina and Mexico. it generates the majority of its revenue from Argentina.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.